Delcath Systems (NASDAQ: DCTH) and ReWalk Robotics (NASDAQ:RWLK) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Insider & Institutional Ownership
0.6% of Delcath Systems shares are held by institutional investors. Comparatively, 4.7% of ReWalk Robotics shares are held by institutional investors. 0.0% of Delcath Systems shares are held by insiders. Comparatively, 13.7% of ReWalk Robotics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Delcath Systems and ReWalk Robotics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ReWalk Robotics has a consensus price target of $4.63, indicating a potential upside of 242.59%. Given ReWalk Robotics’ higher probable upside, analysts clearly believe ReWalk Robotics is more favorable than Delcath Systems.
This table compares Delcath Systems and ReWalk Robotics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Delcath Systems and ReWalk Robotics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Delcath Systems||$2.44 million||7.27||-$17.66 million||N/A||N/A|
|ReWalk Robotics||$7.50 million||3.91||-$24.63 million||($1.94)||-0.70|
Delcath Systems has higher revenue, but lower earnings than ReWalk Robotics.
ReWalk Robotics beats Delcath Systems on 8 of the 10 factors compared between the two stocks.
Delcath Systems Company Profile
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
ReWalk Robotics Company Profile
ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.
Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.